Like so many romances, the impending $277 million marriage between Accuray Inc. (NSDQ:ARAY) and TomoTherapy Inc. (NSDQ:TOMO) began on the shores of the Mediterranean, in the beautiful city of Barcelona.
Accuray/Tomotherapy merger: Did the fish swallow the whale?
Accuray lines up $277 million TomoTherapy buyout | Acquisitions roundup
Accuray Inc. (NSDQ:ARAY) looks set to acquire radiation treatment firm TomoTherapy Inc. (NSDQ:TOMO) in a deal worth $277 million.
The Sunnyvale, Calif.-based radiosurgery company signed an agreement to buy TomoTherapy for $4.80 per share in cash and stock, a nearly 31 percent premium over its $3.67 closing price on Friday, March 4.
The companies believe their technologies complement one another in that they can serve overlapping patient populations.
Clearances roundup: Accuray wins 510(k) for CyberKnife lung cancer treatment
Varian, Imris to co-develop MR-guided cancer device
Varian Medical Systems Inc. (NYSE:VAR) and IMRIS Inc. (TSX:IM) inked a co-development deal to create a magnetic-resonance-guided radiation therapy system to treat cancer.
The deal calls for the integration of Winnipeg, Manitoba-based Imris’ MR imaging technology with Palo Alto, Calif.-based Varian’s TrueBeam radiosurgery device.
- « Previous Page
- 1
- …
- 14
- 15
- 16
MassDevice Network
@MassDevice
LinkedIn
YouTube